Princeton-based pharmaceutical company Soligenix announced Monday it has appointed Dr. Richard Straube as senior vice president and chief medical officer.
According to the announcement, Straube is a board-certified pediatrician with clinical research experience in host-response modulation. He has 35 years of experience in academia and industry, including positions at Centocor, Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides Inc.
Straube received his medical degree and residency training at the University of Chicago, completed a joint adult and pediatrician infectious diseases fellowship at the University of California San Diego, the company said in a statement.
Stay informed: Subscribe to free NJBIZ newsletters
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy